{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:44:57Z","timestamp":1786981497481,"version":"build-2736575974"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82270551"],"award-info":[{"award-number":["No. 82270551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82270551"],"award-info":[{"award-number":["No. 82270551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82270551"],"award-info":[{"award-number":["No. 82270551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82270551"],"award-info":[{"award-number":["No. 82270551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82270551"],"award-info":[{"award-number":["No. 82270551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82270551"],"award-info":[{"award-number":["No. 82270551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82270551"],"award-info":[{"award-number":["No. 82270551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82270551"],"award-info":[{"award-number":["No. 82270551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"crossref","award":["No. 2022ZDLSF03-03"],"award-info":[{"award-number":["No. 2022ZDLSF03-03"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"crossref","award":["No. 2022ZDLSF03-03"],"award-info":[{"award-number":["No. 2022ZDLSF03-03"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"crossref","award":["No. 2022ZDLSF03-03"],"award-info":[{"award-number":["No. 2022ZDLSF03-03"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"crossref","award":["No. 2022ZDLSF03-03"],"award-info":[{"award-number":["No. 2022ZDLSF03-03"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"crossref","award":["No. 2022ZDLSF03-03"],"award-info":[{"award-number":["No. 2022ZDLSF03-03"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"crossref","award":["No. 2022ZDLSF03-03"],"award-info":[{"award-number":["No. 2022ZDLSF03-03"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"crossref","award":["No. 2022ZDLSF03-03"],"award-info":[{"award-number":["No. 2022ZDLSF03-03"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"crossref","award":["No. 2022ZDLSF03-03"],"award-info":[{"award-number":["No. 2022ZDLSF03-03"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-09806-w","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T07:14:16Z","timestamp":1722410056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review"],"prefix":"10.1007","volume":"51","author":[{"given":"Punan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanya","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"9806_CR1","doi-asserted-by":"publisher","unstructured":"Andrade RJ, Chalasani N, Bj\u00f6rnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP (2019) Drug-induced liver injury. Nat Reviews Disease Primers 5. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR2","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41572-019-0105-0","volume":"9","author":"ES Bjornsson","year":"2021","unstructured":"Bjornsson ES (2021) Clinical management of patients with drug-induced liver injury (DILI). United Eur Gastroenterol J 9:781\u2013786. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"United Eur Gastroenterol J"},{"key":"9806_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-019-0105-0","volume":"28","author":"A Licata","year":"2016","unstructured":"Licata A (2016) Adverse drug reactions and organ damage: the liver. Eur J Intern Med 28:9\u201316. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Eur J Intern Med"},{"key":"9806_CR4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/s41572-019-0105-0","volume":"42","author":"X Li","year":"2022","unstructured":"Li X, Tang J, Mao Y (2022) Incidence and risk factors of drug-induced liver injury. Liver Int 42:1999\u20132014. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41572-019-0105-0","volume":"21","author":"H Saithanyamurthi","year":"2017","unstructured":"Saithanyamurthi H, Faust AJ (2017) Drug-Induced Liver Disease. Clin Liver Dis 21:21\u201334. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Clin Liver Dis"},{"key":"9806_CR6","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41572-019-0105-0","volume":"55","author":"RP Hermann","year":"2022","unstructured":"Hermann RP, Rockey DC, Suzuki A, Merz M, Tillmann HL (2022) A novel phenotype-based drug\u2010induced liver injury causality assessment tool (DILI\u2010CAT) allows for signal confirmation in early drug development. Aliment Pharmacol Ther 55:1028\u20131037. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Aliment Pharmacol Ther"},{"key":"9806_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41572-019-0105-0","volume":"15","author":"H Devarbhavi","year":"2021","unstructured":"Devarbhavi H, Aithal G, Treeprasertsuk S, Takikawa H, Mao Y, Shasthry SM, Hamid S, Tan SS, Philips CA, George J et al (2021) Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hep Intl 15:258\u2013282. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hep Intl"},{"key":"9806_CR8","doi-asserted-by":"publisher","unstructured":"Li M, Luo Q, Tao Y, Sun X, Liu C (2022) Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review. Front Pharmacol 12. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41572-019-0105-0","volume":"39","author":"A Hassan","year":"2018","unstructured":"Hassan A, Fontana RJ (2018) The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int 39:31\u201341. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41572-019-0105-0","volume":"97","author":"HK Bj\u00f6rnsson","year":"2022","unstructured":"Bj\u00f6rnsson HK, Bj\u00f6rnsson ES (2022) Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med 97:26\u201331. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Eur J Intern Med"},{"key":"9806_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41572-019-0105-0","volume":"26","author":"R Allison","year":"2023","unstructured":"Allison R, Guraka A, Shawa IT, Tripathi G, Moritz W, Kermanizadeh A (2023) Drug induced liver injury \u2013 a 2023 update. J Toxicol Environ Health Part B 26:442\u2013467. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Toxicol Environ Health Part B"},{"key":"9806_CR12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41572-019-0105-0","volume":"17","author":"M Yan","year":"2018","unstructured":"Yan M, Huo Y, Yin S, Hu H (2018) Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions. Redox Biol 17:274\u2013283. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Redox Biol"},{"key":"9806_CR13","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41572-019-0105-0","volume":"77","author":"RJ Fontana","year":"2023","unstructured":"Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, Navarro V (2023) AASLD practice guidance on drug, herbal, and dietary supplement\u2013induced liver injury. Hepatology 77:1036\u20131065. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hepatology"},{"key":"9806_CR14","doi-asserted-by":"publisher","unstructured":"Yu Y-c, Mao Y-m, Chen C-w, Chen J-j, Chen J, Cong W-m, Ding Y, Duan Z et al (2017) -p, Fu Q-c, Guo X-y, CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatology International, 11:221\u2013241. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR15","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s41572-019-0105-0","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H et al (2015) Features and outcomes of 899 patients with Drug-Induced Liver Injury: the DILIN prospective study. Gastroenterology 148:1340\u20131352e1347. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Gastroenterology"},{"key":"9806_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","author":"S Timmermans","year":"2019","unstructured":"Timmermans S, Souffriau J, Libert C (2019) A General introduction to Glucocorticoid Biology. Front Immunol. 10https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Front Immunol"},{"key":"9806_CR17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41572-019-0105-0","volume":"57","author":"HR Lesesne","year":"1973","unstructured":"Lesesne HR, Fallon HJ (1973) Treatment of Liver Disease with corticosteroids. Med Clin North Am 57:1191\u20131201. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Med Clin North Am"},{"key":"9806_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41572-019-0105-0","volume":"42","author":"S Tujios","year":"2022","unstructured":"Tujios S, Stravitz RT, Lee WM (2022) Management of Acute Liver failure: Update 2022. Semin Liver Dis 42:362\u2013378. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Semin Liver Dis"},{"key":"9806_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","author":"R Xue","year":"2019","unstructured":"Xue R, Meng Q (2019) The management of glucocorticoid therapy in liver failure. Front Immunol. 10https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Front Immunol"},{"key":"9806_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","author":"C Ye","year":"2022","unstructured":"Ye C, Li W, Li L, Zhang K (2022) Glucocorticoid treatment strategies in liver failure. Front Immunol. 13https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Front Immunol"},{"key":"9806_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"27","author":"A Komori","year":"2021","unstructured":"Komori A (2021) Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol 27:58\u201369. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Clin Mol Hepatol"},{"key":"9806_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41572-019-0105-0","volume":"113","author":"AK Singal","year":"2018","unstructured":"Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH (2018) ACG Clinical Guideline: alcoholic liver disease. Am J Gastroenterol 113:175\u2013194. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Am J Gastroenterol"},{"key":"9806_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41572-019-0105-0","volume":"101","author":"M Mosedale","year":"2017","unstructured":"Mosedale M, Watkins PB (2017) Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther 101:469\u2013480. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Clin Pharmacol Ther"},{"key":"9806_CR24","doi-asserted-by":"publisher","unstructured":"Pu S, Pan Y, Zhang Q, You T, Yue T, Zhang Y, Wang M (2023) Endoplasmic reticulum stress and mitochondrial stress in Drug-Induced Liver Injury. Molecules 28. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR25","doi-asserted-by":"publisher","unstructured":"Villanueva-Paz M, Mor\u00e1n L, L\u00f3pez-Alc\u00e1ntara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ (2021) Oxidative stress in Drug-Induced Liver Injury (DILI): from mechanisms to biomarkers for Use in Clinical Practice. Antioxidants, p 10. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR26","doi-asserted-by":"publisher","unstructured":"Ortega-Alonso A, Stephens C, Lucena M, Andrade R (2016) Case characterization, clinical features and risk factors in Drug-Induced Liver Injury. Int J Mol Sci 17. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR27","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41572-019-0105-0","volume":"66","author":"GA Kullak-Ublick","year":"2017","unstructured":"Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP (2017) Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 66:1154\u20131164. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Gut"},{"key":"9806_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41572-019-0105-0","volume":"67","author":"TJ Urban","year":"2017","unstructured":"Urban TJ, Nicoletti P, Chalasani N, Serrano J, Stolz A, Daly AK, Aithal GP, Dillon J, Navarro V, Odin J et al (2017) Minocycline hepatotoxicity: clinical characterization and identification of HLA-B\u221735:02 as a risk factor. J Hepatol 67:137\u2013144. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Hepatol"},{"key":"9806_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0105-0","volume":"22","author":"D Cruz-Topete","year":"2015","unstructured":"Cruz-Topete D, Cidlowski JA (2015) One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation 22:20\u201332. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Neuroimmunomodulation"},{"key":"9806_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41572-019-0105-0","volume":"53","author":"AP Syed","year":"2020","unstructured":"Syed AP, Greulich F, Ansari SA, Uhlenhaut NH (2020) Anti-inflammatory glucocorticoid action: genomic insights and emerging concepts. Curr Opin Pharmacol 53:35\u201344. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Curr Opin Pharmacol"},{"key":"9806_CR31","doi-asserted-by":"publisher","unstructured":"Teschke R, Biomedicines (2022) 11. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR32","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1038\/s41572-019-0105-0","volume":"184","author":"N Wuillemin","year":"2014","unstructured":"Wuillemin N, Terracciano L, Beltraminelli H, Schlapbach C, Fontana S, Kr\u00e4henb\u00fchl S, Pichler WJ, Yerly D (2014) T cells infiltrate the liver and kill hepatocytes in HLA-B\u221757:01-Associated Floxacillin-Induced Liver Injury. Am J Pathol 184:1677\u20131682. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Am J Pathol"},{"key":"9806_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41572-019-0105-0","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17:233\u2013247. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Nat Rev Immunol"},{"key":"9806_CR34","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1038\/s41572-019-0105-0","volume":"21","author":"RJ Fontana","year":"2023","unstructured":"Fontana RJ, Bjornsson ES, Reddy R, Andrade RJ (2023) The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. Clin Gastroenterol Hepatol 21:2088\u20132099. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9806_CR35","doi-asserted-by":"publisher","unstructured":"Bj\u00f6rnsson ES, Vucic V, Stirnimann G, Robles-D\u00edaz M (2022) Role of corticosteroids in Drug-Induced Liver Injury. Syst Rev Front Pharmacol 13. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41572-019-0105-0","volume":"84","author":"A Wree","year":"2011","unstructured":"Wree A, Dech\u00eane A, Herzer K, Hilgard P, Syn W-K, Gerken G, Canbay A (2011) Steroid and ursodesoxycholic acid combination therapy in severe Drug-Induced Liver Injury. Digestion 84:54\u201359. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Digestion"},{"key":"9806_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41572-019-0105-0","volume":"38","author":"J Borlak","year":"2017","unstructured":"Borlak J, van B\u00f6mmel F, Berg T (2017) N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury. Liver Int 38:365\u2013376. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR38","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/s41572-019-0105-0","volume":"118","author":"RJ Fontana","year":"2023","unstructured":"Fontana RJ, Kleiner DE, Chalasani N, Bonkovsky H, Gu J, Barnhart H, Li Y-J, Hoofnagle JH (2023) The impact of patient age and corticosteroids in patients with Sulfonamide Hepatotoxicity. Am J Gastroenterol 118:1566\u20131575. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Am J Gastroenterol"},{"key":"9806_CR39","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/s41572-019-0105-0","volume":"57","author":"H Niu","year":"2022","unstructured":"Niu H, Ma J, Medina-Caliz I, Robles\u2010Diaz M, Bonilla\u2010Toyos E, Ghabril M, Lucena MI, Alvarez\u2010Alvarez I, Andrade RJ (2022) Potential benefit and lack of serious risk from corticosteroids in drug\u2010induced liver injury: an international, multicentre, propensity score\u2010matched analysis. Aliment Pharmacol Ther 57:886\u2013896. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Aliment Pharmacol Ther"},{"key":"9806_CR40","doi-asserted-by":"publisher","unstructured":"Wan Y-M, Wu J-F, Li Y-H, Wu H-M, Wu X-N, Xu Y (2019) Prednisone is not beneficial for the treatment of severe drug-induced liver injury. Medicine 98. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41572-019-0105-0","volume":"42","author":"L Pang","year":"2018","unstructured":"Pang L, Yang W, Hou F (2018) Features and outcomes from a retrospective study of 570 hospitalized Chinese patients with drug-induced liver injury. Clin Res Hepatol Gastroenterol 42:48\u201356. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"9806_CR42","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/s41572-019-0105-0","volume":"40","author":"K Kakisaka","year":"2020","unstructured":"Kakisaka K, Suzuki Y, Takikawa Y (2020) Disease severity of acute liver injury caused by drug-induced liver injury may affect the response to corticosteroid therapy. Liver Int 40:1781\u20131781. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR43","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41572-019-0105-0","volume":"28","author":"X Wang","year":"2020","unstructured":"Wang X, Xu H-r, Wang Y-d, Shen C, Zhao C-y (2020) Liver failure and glucocorticoid resistance. Chin J Hepatol 28:888\u2013892. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Chin J Hepatol"},{"key":"9806_CR44","doi-asserted-by":"publisher","unstructured":"Parlati L, Marcin K, Terris B, Vallet-Pichard A, Corouge M, Hollande C, Sogni P, Mallet V, Pol S (2023) Histological characteristics and management of Hepatitis on Immune Checkpoint inhibitors: a Retrospective descriptive study. J Clin Med 12. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-019-0105-0","volume":"40","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Robles-D\u00edaz M (2019) Diagnostic and prognostic assessment of suspected drug\u2010induced liver injury in clinical practice. Liver Int 40:6\u201317. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR46","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41572-019-0105-0","volume":"59","author":"DE Kleiner","year":"2013","unstructured":"Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R et al (2013) Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59:661\u2013670. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hepatology"},{"key":"9806_CR47","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"MI Lucena","year":"2020","unstructured":"Lucena MI, Sanabria J, Garc\u00eda-Cortes M, Stephens C, Andrade RJ (2020) Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol 5:862\u2013874. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9806_CR48","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41572-019-0105-0","volume":"118","author":"A Shingina","year":"2023","unstructured":"Shingina A, Mukhtar N, Wakim-Fleming J, Alqahtani S, Wong RJ, Limketkai BN, Larson AM, Grant L (2023) Acute Liver failure guidelines. Am J Gastroenterol 118:1128\u20131153. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Am J Gastroenterol"},{"key":"9806_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41572-019-0105-0","volume":"20","author":"PF Hu","year":"2019","unstructured":"Hu PF, Xie WF (2019) Corticosteroid therapy in drug-induced liver injury: pros and cons. J Dig Dis 20:122\u2013126. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Dig Dis"},{"key":"9806_CR50","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41572-019-0105-0","volume":"17","author":"PF Hu","year":"2016","unstructured":"Hu PF, Wang PQ, Chen H, Hu XF, Xie QP, Shi J, Lin L, Xie WF (2016) Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis 17:618\u2013627. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Dig Dis"},{"key":"9806_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","author":"Y Mao","year":"2024","unstructured":"Mao Y, Ma S, Liu C, Liu X, Su M, Li D, Li Y, Chen G, Chen J, Chen J et al (2024) Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update. Hep Intl. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hep Intl"},{"key":"9806_CR52","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41572-019-0105-0","volume":"12","author":"BA Asif","year":"2024","unstructured":"Asif BA, Koh C, Phillips EJ, Gu J, Li Y-J, Barnhart H, Chalasani N, Fontana RJ, Hayashi PH, Navarro VJ, Hoofnagle JH (2024) Vancomycin-Induced Liver Injury, DRESS, and HLA-A\u221732:01. J Allergy Clin Immunology: Pract 12:168\u2013174e162. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"9806_CR53","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41572-019-0105-0","volume":"56","author":"R Vuppalanchi","year":"2022","unstructured":"Vuppalanchi R, Ghabril M (2022) Review article: clinical assessment of suspected drug-induced liver injury and its management. Aliment Pharmacol Ther 56:1516\u20131531. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Aliment Pharmacol Ther"},{"key":"9806_CR54","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/s41572-019-0105-0","volume":"14","author":"F Bessone","year":"2022","unstructured":"Bessone F, Bjornsson ES (2022) Checkpoint inhibitor-induced hepatotoxicity: role of liver biopsy and management approach. World J Hepatol 14:1269\u20131276. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"World J Hepatol"},{"key":"9806_CR55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41572-019-0105-0","volume":"43","author":"R Sheth","year":"2023","unstructured":"Sheth R, Gudd CLC, Thursz MR, Triantafyllou E, Possamai LA (2023) Immune Checkpoint inhibitor-Induced Liver Injury. Semin Liver Dis 43:402\u2013417. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Semin Liver Dis"},{"key":"9806_CR56","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41572-019-0105-0","volume":"59","author":"J Karkhanis","year":"2014","unstructured":"Karkhanis J, Verna EC, Chang MS, Stravitz RT, Schilsky M, Lee WM, Brown RS (2014) Steroid use in acute liver failure. Hepatology 59:612\u2013621. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hepatology"},{"key":"9806_CR57","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/s41572-019-0105-0","volume":"52","author":"K Kakisaka","year":"2017","unstructured":"Kakisaka K, Kataoka K, Suzuki Y, Kuroda H, Takikawa Y (2017) Appropriate timing to start and optimal response evaluation of high-dose corticosteroid therapy for patients with acute liver failure. J Gastroenterol 52:977\u2013985. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Gastroenterol"},{"key":"9806_CR58","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41572-019-0105-0","volume":"381","author":"JH Hoofnagle","year":"2019","unstructured":"Hoofnagle JH, Longo DL, Bj\u00f6rnsson ES (2019) Drug-Induced Liver Injury \u2014 types and phenotypes. N Engl J Med 381:264\u2013273. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"N Engl J Med"},{"key":"9806_CR59","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41572-019-0105-0","volume":"10","author":"JG Stine","year":"2015","unstructured":"Stine JG, Lewis JH (2015) Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol 10:517\u2013536. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"9806_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0105-0","volume":"24","author":"ES Bj\u00f6rnsson","year":"2020","unstructured":"Bj\u00f6rnsson ES (2020) Epidemiology, predisposing factors, and outcomes of Drug-Induced Liver Injury. Clin Liver Dis 24:1\u201310. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Clin Liver Dis"},{"key":"9806_CR61","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41572-019-0105-0","volume":"66","author":"J Wendon","year":"2017","unstructured":"Wendon J, Cordoba J, Dhawan A, Larsen FS, Manns M, Nevens F, Samuel D, Simpson KJ, Yaron I, Bernardi M (2017) EASL Clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol 66:1047\u20131081. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Hepatol"},{"key":"9806_CR62","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-019-0105-0","volume":"38","author":"SR Tujios","year":"2017","unstructured":"Tujios SR, Lee WM (2017) Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy. Liver Int 38:6\u201314. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR63","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41572-019-0105-0","volume":"70","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Aithal GP, Bj\u00f6rnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, Karlsen TH (2019) EASL Clinical Practice guidelines: drug-induced liver injury. J Hepatol 70:1222\u20131261. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Hepatol"},{"key":"9806_CR64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41572-019-0105-0","volume":"24","author":"M Chayanupatkul","year":"2020","unstructured":"Chayanupatkul M, Schiano TD (2020) Acute Liver failure secondary to Drug-Induced Liver Injury. Clin Liver Dis 24:75\u201387. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Clin Liver Dis"},{"key":"9806_CR65","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41572-019-0105-0","volume":"21","author":"M Garc\u00eda-Cort\u00e9s","year":"2021","unstructured":"Garc\u00eda-Cort\u00e9s M, Ortega-Alonso A, Andrade RJ (2021) Safety of treating acute liver injury and failure. Exp Opin Drug Saf 21:191\u2013203. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Exp Opin Drug Saf"},{"key":"9806_CR66","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41572-019-0105-0","volume":"149","author":"A Miah","year":"2022","unstructured":"Miah A, Tinoco G, Zhao S, Wei L, Johns A, Patel S, Li M, Grogan M, Lopez G, Husain M et al (2022) Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. J Cancer Res Clin Oncol 149:2235\u20132242. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Cancer Res Clin Oncol"},{"key":"9806_CR67","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41572-019-0105-0","volume":"13","author":"N Nishida","year":"2019","unstructured":"Nishida N, Kudo M (2019) Liver damage related to immune checkpoint inhibitors. Hep Intl 13:248\u2013252. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hep Intl"},{"key":"9806_CR68","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1038\/s41572-019-0105-0","volume":"27","author":"D Remash","year":"2021","unstructured":"Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K (2021) Immune checkpoint inhibitor-related hepatotoxicity: a review. World J Gastroenterol 27:5376\u20135391. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"World J Gastroenterol"},{"key":"9806_CR69","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/s41572-019-0105-0","volume":"57","author":"T Matsubara","year":"2018","unstructured":"Matsubara T, Nishida T, Higaki Y, Tomita R, Shimakoshi H, Shimoda A, Osugi N, Sugimoto A, Takahashi K, Nakamatsu D et al (2018) Nivolumab induces sustained Liver Injury in a patient with malignant melanoma. Intern Med 57:1789\u20131792. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Intern Med"},{"key":"9806_CR70","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41572-019-0105-0","volume":"41","author":"BM Huffman","year":"2018","unstructured":"Huffman BM, Kottschade LA, Kamath PS, Markovic SN (2018) Hepatotoxicity after Immune checkpoint inhibitor therapy in Melanoma. Am J Clin Oncol 41:760\u2013765. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Am J Clin Oncol"},{"key":"9806_CR71","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41572-019-0105-0","volume":"59","author":"M Riveiro-Barciela","year":"2024","unstructured":"Riveiro-Barciela M, Barreira\u2010D\u00edaz A, Salcedo MT, Callejo\u2010P\u00e9rez A, Mu\u00f1oz\u2010Couselo E, Iranzo P, Ortiz\u2010Velez C, Cedr\u00e9s S, D\u00edaz\u2010Mej\u00eda N, Ruiz\u2010Cobo JC et al (2024) An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor\u2010induced liver injury. Aliment Pharmacol Ther 59:865\u2013876. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Aliment Pharmacol Ther"},{"key":"9806_CR72","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41572-019-0105-0","volume":"44","author":"JW Clinton","year":"2021","unstructured":"Clinton JW, Kiparizoska S, Aggarwal S, Woo S, Davis W, Lewis JH (2021) Drug-Induced Liver Injury: highlights and controversies in the recent literature. Drug Saf 44:1125\u20131149. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Drug Saf"},{"key":"9806_CR73","doi-asserted-by":"publisher","unstructured":"Gauci M-L, Baroudjian B, B\u00e9d\u00e9r\u00e8de U, Zeboulon C, Delyon J, Allayous C, Madelaine I, Eftekhari P, Resche-Rigon M, Pot\u00e9 N et al (2021) Severe immune-related hepatitis induced by immune checkpoint inhibitors: clinical features and management proposal. Clin Res Hepatol Gastroenterol 45. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR74","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41572-019-0105-0","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot J-M, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S et al (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68:1181\u20131190. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Hepatol"},{"key":"9806_CR75","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41572-019-0105-0","volume":"96","author":"C Meyerson","year":"2020","unstructured":"Meyerson C, Naini BV (2020) Something old, something new: liver injury associated with total parenteral nutrition therapy and immune checkpoint inhibitors. Hum Pathol 96:39\u201347. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hum Pathol"},{"key":"9806_CR76","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41572-019-0105-0","volume":"79","author":"M Cunningham","year":"2024","unstructured":"Cunningham M, Gupta R, Butler M (2024) Checkpoint inhibitor hepatotoxicity: pathogenesis and management. Hepatology 79:198\u2013212. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hepatology"},{"key":"9806_CR77","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41572-019-0105-0","volume":"115","author":"ED Miller","year":"2020","unstructured":"Miller ED, Abu-Sbeih H, Styskel B, Nogueras Gonzalez GM, Blechacz B, Naing A, Chalasani N (2020) Clinical characteristics and adverse impact of Hepatotoxicity due to Immune Checkpoint inhibitors. Am J Gastroenterol 115:251\u2013261. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Am J Gastroenterol"},{"key":"9806_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","author":"N Zhang","year":"2024","unstructured":"Zhang N, Li Z, Liu Y, Shi X, Shi D, Li Y, Si X, Xun Z, Shao J, Zhao H, Wang H (2024) Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics. Hep Intl. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hep Intl"},{"key":"9806_CR79","doi-asserted-by":"publisher","unstructured":"Li M, Wong D, Vogel AS, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S (2022) Effect of corticosteroid dosing on outcomes in high-\u00adgrade immune checkpoint inhibitor hepatitis Hepatology. 75:531\u2013540. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR80","doi-asserted-by":"publisher","unstructured":"Regev A, Avigan MI, Kiazand A, Vierling JM, Lewis JH, Omokaro SO, Di Bisceglie AM, Fontana RJ, Bonkovsky HL, Freston JW et al (2020) Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun 114. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR81","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/s41572-019-0105-0","volume":"15","author":"T Ito","year":"2021","unstructured":"Ito T, Ishigami M, Yamamoto T, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H, Yasuda S et al (2021) Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. Hep Intl 15:1278\u20131287. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hep Intl"},{"key":"9806_CR82","doi-asserted-by":"publisher","unstructured":"Ueno M, Takabatake H, Hata A, Kayahara T, Morimoto Y, Notohara K, Mizuno M (2022) Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: a report of two cases and literature review. Cancer Rep 5. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR83","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41572-019-0105-0","volume":"66","author":"M Ziemer","year":"2017","unstructured":"Ziemer M, Koukoulioti E, Beyer S, Simon JC, Berg T (2017) Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol 66:657\u2013659. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Hepatol"},{"key":"9806_CR84","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41572-019-0105-0","volume":"79","author":"RJ Andrade","year":"2023","unstructured":"Andrade RJ, Aithal GP, de Boer YS, Liberal R, Gerbes A, Regev A, Terziroli Beretta-Piccoli B, Schramm C, Kleiner DE, De Martin E et al (2023) Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report. J Hepatol 79:853\u2013866. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Hepatol"},{"key":"9806_CR85","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0105-0","volume":"12","author":"Y Chung","year":"2023","unstructured":"Chung Y, Morrison M, Zen Y, Heneghan MA (2023) Defining characteristics and long-term prognosis of drug\u2010induced autoimmune\u2010like hepatitis: a retrospective cohort study. United Eur Gastroenterol J 12:66\u201375. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"United Eur Gastroenterol J"},{"key":"9806_CR86","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41572-019-0105-0","volume":"43","author":"M Garc\u00eda-Cort\u00e9s","year":"2023","unstructured":"Garc\u00eda-Cort\u00e9s M, Ortega\u2010Alonso A, Matilla\u2010Cabello G, Medina\u2010C\u00e1liz I, Castiella A, Conde I, Bonilla\u2010Toyos E, Pinazo\u2010Bandera J, Hern\u00e1ndez N, Tagle M et al (2023) Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries. Liver Int 43:1749\u20131760. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR87","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41572-019-0105-0","volume":"166","author":"L Dara","year":"2024","unstructured":"Dara L, Ghabril M, Phillips E, Kleiner D, Chalasani N (2024) A 68-Year-old woman with unexplained liver enzyme elevation and active chronic Hepatitis: beware of Drug-Induced Autoimmune-Like Hepatitis. Gastroenterology 166:259\u2013266e251. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Gastroenterology"},{"key":"9806_CR88","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41572-019-0105-0","volume":"78","author":"N Chalasani","year":"2023","unstructured":"Chalasani N, Li Y-J, Dellinger A, Navarro V, Bonkovsky H, Fontana RJ, Gu J, Barnhart H, Phillips E, Lammert C et al (2023) Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury. J Hepatol 78:293\u2013300. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Hepatol"},{"key":"9806_CR89","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41572-019-0105-0","volume":"46","author":"A Licata","year":"2014","unstructured":"Licata A, Maida M, Cabibi D, Butera G, Macaluso FS, Alessi N, Caruso C, Crax\u00ec A, Almasio PL (2014) Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. Dig Liver Disease 46:1116\u20131120. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Dig Liver Disease"},{"key":"9806_CR90","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41572-019-0105-0","volume":"34","author":"AS deLemos","year":"2014","unstructured":"deLemos AS, Foureau DM, Jacobs C, Ahrens W, Russo MW, Bonkovsky HL (2014) Drug-Induced Liver Injury with Autoimmune features. Semin Liver Dis 34:194\u2013204. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Semin Liver Dis"},{"key":"9806_CR91","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41572-019-0105-0","volume":"15","author":"ES Bj\u00f6rnsson","year":"2017","unstructured":"Bj\u00f6rnsson ES, Bergmann O, Jonasson JG, Grondal G, Gudbjornsson B, Olafsson S (2017) Drug-Induced Autoimmune Hepatitis: response to corticosteroids and lack of Relapse after Cessation of steroids. Clin Gastroenterol Hepatol 15:1635\u20131636. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9806_CR92","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-019-0105-0","volume":"76","author":"HK Bj\u00f6rnsson","year":"2022","unstructured":"Bj\u00f6rnsson HK, Gudbjornsson B, Bj\u00f6rnsson ES (2022) Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment. J Hepatol 76:86\u201392. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Hepatol"},{"key":"9806_CR93","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1038\/s41572-019-0105-0","volume":"39","author":"S Weber","year":"2019","unstructured":"Weber S, Benesic A, Rotter I, Gerbes AL (2019) Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver Int 39:1906\u20131917. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR94","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41572-019-0105-0","volume":"104","author":"S Weber","year":"2023","unstructured":"Weber S, Gerbes AL (2023) Relapse and need for extended immunosuppression: Novel features of Drug-Induced Autoimmune Hepatitis. Digestion 104:243\u2013248. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Digestion"},{"key":"9806_CR95","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41572-019-0105-0","volume":"15","author":"YS de Boer","year":"2017","unstructured":"de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, Kleiner DE, Hoofnagle JH (2017) Features of Autoimmune Hepatitis in patients with drug-induced Liver Injury. Clin Gastroenterol Hepatol 15:103\u2013112e102. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9806_CR96","doi-asserted-by":"publisher","unstructured":"Wang Q, Huang A, Wang J-B, Zou Z (2021) Chronic Drug-Induced Liver Injury: Updates and Future challenges. Front Pharmacol 12. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR97","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41572-019-0105-0","volume":"39","author":"F Bessone","year":"2019","unstructured":"Bessone F, Robles-Diaz M, Hernandez N, Medina-Caliz I, Lucena MI, Andrade RJ (2019) Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. Semin Liver Dis 39:381\u2013394. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Semin Liver Dis"},{"key":"9806_CR98","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41572-019-0105-0","volume":"65","author":"I Medina-Caliz","year":"2016","unstructured":"Medina-Caliz I, Robles-Diaz M, Garcia-Mu\u00f1oz B, Stephens C, Ortega-Alonso A, Garcia-Cortes M, Gonz\u00e1lez-Jimenez A, Sanabria-Cabrera JA, Moreno I, Fernandez MC et al (2016) Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol 65:532\u2013542. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Hepatol"},{"key":"9806_CR99","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/s41572-019-0105-0","volume":"35","author":"JG Stine","year":"2015","unstructured":"Stine JG, Chalasani N (2015) Chronic liver injury induced by drugs: a systematic review. Liver Int 35:2343\u20132353. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR100","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/s41572-019-0105-0","volume":"55","author":"JB Wang","year":"2022","unstructured":"Wang JB, Huang A, Wang Y, Ji D, Liang QS, Zhao J, Zhou G, Liu S, Niu M, Sun Y et al (2022) Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb\u2010induced liver injury achieves biochemical and histological improvements: a randomised open\u2010label trial. Aliment Pharmacol Ther 55:1297\u20131310. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Aliment Pharmacol Ther"},{"key":"9806_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0105-0","volume":"44","author":"A Huang","year":"2024","unstructured":"Huang A, Zhu Y, Liu S-h, Sun Y, Liu Z-r, Liang Q-s, Zhao J, Chang B-x, Bi J-f, Liu J-t et al (2024) An optimized short-\u00adterm steroid therapy for chronic drug-\u00adinduced liver injury: a prospective randomized clinical trial. Liver Int 44:1\u201313. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR102","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41572-019-0105-0","volume":"10","author":"N Hama","year":"2022","unstructured":"Hama N, Abe R, Gibson A, Phillips EJ (2022) Drug-Induced Hypersensitivity Syndrome (DIHS)\/Drug reaction with Eosinophilia and systemic symptoms (DRESS): clinical features and Pathogenesis. J Allergy Clin Immunology: Pract 10:1155\u20131167e1155. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"9806_CR103","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41572-019-0105-0","volume":"77","author":"S Sharifzadeh","year":"2020","unstructured":"Sharifzadeh S, Mohammadpour AH, Tavanaee A, Elyasi S (2020) Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. Eur J Clin Pharmacol 77:275\u2013289. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Eur J Clin Pharmacol"},{"key":"9806_CR104","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41572-019-0105-0","volume":"98","author":"I Medina-C\u00e1liz","year":"2023","unstructured":"Medina-C\u00e1liz I, Sanabria-Cabrera J, Villanueva-Paz M, Auk\u0161tikaln\u0117 L, Stephens C, Robles-D\u00edaz M, Pinazo-Bandera JM, Garc\u00eda-Cortes M, Conde I, Soriano G et al (2023) Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries. Arch Toxicol 98:303\u2013325. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Arch Toxicol"},{"key":"9806_CR105","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41572-019-0105-0","volume":"39","author":"H Devarbhavi","year":"2018","unstructured":"Devarbhavi H, Raj S (2018) Drug-induced liver injury with skin reactions: drugs and host risk factors, clinical phenotypes and prognosis. Liver Int 39:802\u2013811. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR106","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41572-019-0105-0","volume":"90","author":"BM Wei","year":"2024","unstructured":"Wei BM, Fox LP, Kaffenberger BH, Korman AM, Micheletti RG, Mostaghimi A, Noe MH, Rosenbach M, Shinkai K, Kwah JH et al (2024) Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. J Am Acad Dermatol 90:911\u2013926. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"J Am Acad Dermatol"},{"key":"9806_CR107","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/s41572-019-0105-0","volume":"117","author":"H Devarbhavi","year":"2022","unstructured":"Devarbhavi H, Kurien SS, Raj S, Patil M, Gowda V, Kothari K, Singh R (2022) Idiosyncratic Drug-Induced Liver Injury Associated with and without drug reaction with Eosinophilia and systemic symptoms. Am J Gastroenterol 117:1709\u20131713. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Am J Gastroenterol"},{"key":"9806_CR108","doi-asserted-by":"publisher","unstructured":"Zhao Z, Lu M, Ying Y (2024) Case Report: Minocycline-induced drug reaction with eosinophilia and systemic symptoms syndrome: a case report and literature review. Front Pharmacol 15. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR109","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41572-019-0105-0","volume":"44","author":"M Irabien","year":"2021","unstructured":"Irabien M, Blanco S, Calder\u00f3n \u00c1 (2021) DRESS syndrome and drug-induced liver injury owing to antituberculous treatment. Gastroenterolog\u00eda Y Hepatolog\u00eda (English Edition) 44:427\u2013428. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Gastroenterolog\u00eda Y Hepatolog\u00eda (English Edition)"},{"key":"9806_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","author":"A Miyasaka","year":"2021","unstructured":"Miyasaka A, Kumagai I, Masuda T, Takikawa Y (2021) A 51-Year-old woman with Drug-Induced Hypersensitivity Syndrome Associated with Carbamazepine, Reactivation of Human Herpesvirus 6, and Acute Liver failure: a Case Report. Am J Case Rep. 22https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Am J Case Rep"},{"key":"9806_CR111","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41572-019-0105-0","volume":"27","author":"S Mirza","year":"2017","unstructured":"Mirza S, Hill E, Ludlow SP, Nanjappa S (2017) Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res 27:271\u2013273. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Melanoma Res"},{"key":"9806_CR112","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1038\/s41572-019-0105-0","volume":"41","author":"YS Huang","year":"2021","unstructured":"Huang YS, Wu CY, Chang TT, Peng CY, Lo GH, Hsu CW, Hu CT, Huang YH (2021) Drug-induced liver injury associated with severe cutaneous adverse drug reactions: a nationwide study in Taiwan. Liver Int 41:2671\u20132680. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Liver Int"},{"key":"9806_CR113","doi-asserted-by":"publisher","unstructured":"Br\u00fcggen M-C, Walsh S, Ameri MM, Anasiewicz N, Maverakis E, French LE, Ingen-Housz-Oro S, Abe R, Ardern-Jones M, Assier H et al (2024) Management of adult patients with drug reaction with Eosinophilia and systemic symptoms. JAMA Dermatology 160. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR114","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41572-019-0105-0","volume":"21","author":"I Dobreva","year":"2020","unstructured":"Dobreva I, Karagyozov P (2020) Drug-induced bile Duct Injury - A Short Review. Curr Drug Metab 21:256\u2013259. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Curr Drug Metab"},{"key":"9806_CR115","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41572-019-0105-0","volume":"41","author":"F Bessone","year":"2021","unstructured":"Bessone F, Hern\u00e1ndez N, Tanno M, Roma MG (2021) Drug-Induced vanishing bile Duct Syndrome: from pathogenesis to diagnosis and therapeutics. Semin Liver Dis 41:331\u2013348. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Semin Liver Dis"},{"key":"9806_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","author":"MJ Eiswerth","year":"2022","unstructured":"Eiswerth MJ, Heckroth MA, Ismail A, Gondim DD, Kaufman R (2022) Infliximab-Induced vanishing bile Duct Syndrome. Cureus. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Cureus"},{"key":"9806_CR117","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41572-019-0105-0","volume":"14","author":"G Maria","year":"2021","unstructured":"Maria G, Marco C, MariaI A, Maddalena M, Nicola Z, Francesca C, Pietro I, Paolo B, Diego C (2021) Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. Immunotherapy 14:175\u2013181. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Immunotherapy"},{"key":"9806_CR118","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s41572-019-0105-0","volume":"65","author":"HL Bonkovsky","year":"2017","unstructured":"Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, Fontana RJ, Ghabril MS, Barnhart H, Hoofnagle JH (2017) Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology 65:1267\u20131277. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hepatology"},{"key":"9806_CR119","doi-asserted-by":"publisher","unstructured":"Bak H, Kim H, Lee S, Lee Y, Bang S-M, Lee Y-S (2020) A case of vanishing bile Duct Syndrome after Drug-Induced Liver Injury caused by Pelubiprofen. Yonsei Med J 61. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","author":"S Piawah","year":"2019","unstructured":"Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ (2019) A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. npj Breast Cancer. 5https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"npj Breast Cancer"},{"key":"9806_CR121","doi-asserted-by":"publisher","unstructured":"Izzo P, Gallo G, Codacci Pisanelli M, D\u2019Onghia G, Macci L, Gabriele R, Polistena A, Izzo L, Izzo S, Basso L (2022) Vanishing bile Duct Syndrome in an adult patient: Case Report and Review of the literature. J Clin Med 11. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR122","doi-asserted-by":"publisher","unstructured":"Wasuwanich P, Choudry H, So JM, Lowry S, Karnsakul W (2022) Vanishing bile duct syndrome after drug-induced liver injury. Clin Res Hepatol Gastroenterol 46. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR123","doi-asserted-by":"publisher","unstructured":"Shionoya K, Kobayashi M, Kako M, Masuda S, Makazu M, Koizumi K (2024) A case of drug-induced Liver Injury considered steroid-resistant and histologically diagnosed with vanishing bile Duct Syndrome. https:\/\/doi.org\/10.1038\/s41572-019-0105-0. Internal Medicine","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR124","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41572-019-0105-0","volume":"44","author":"R Pofi","year":"2023","unstructured":"Pofi R, Caratti G, Ray DW, Tomlinson JW (2023) Treating the Side effects of Exogenous glucocorticoids; can we separate the good from the bad? Endocr Rev 44:975\u20131011. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Endocr Rev"},{"key":"9806_CR125","doi-asserted-by":"publisher","unstructured":"Kulkarni S, Durham H, Glover L, Ather O, Phillips V, Nemes S, Cousens L, Blomgran P, Ambery P (2022) Metabolic adverse events associated with systemic corticosteroid therapy\u2014a systematic review and meta-analysis. BMJ Open 12. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","DOI":"10.1038\/s41572-019-0105-0"},{"key":"9806_CR126","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/s41572-019-0105-0","volume":"59","author":"MJ Townsend","year":"2024","unstructured":"Townsend MJ, Benque IJ, Li M, Grover S (2024) Review article: contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors. Aliment Pharmacol Ther 59:1350\u20131365. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Aliment Pharmacol Ther"},{"key":"9806_CR127","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41572-019-0105-0","volume":"70","author":"O Caster","year":"2014","unstructured":"Caster O, Conforti A, Viola E, Edwards IR (2014) Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance. Eur J Clin Pharmacol 70:501\u2013503. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Eur J Clin Pharmacol"},{"key":"9806_CR128","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41572-019-0105-0","volume":"44","author":"J Cottin","year":"2020","unstructured":"Cottin J, Pierre S, Pizzoglio V, Simon C, Durrieu G, Bleyzac N, Gouraud A, Dumortier J (2020) Methylprednisolone-related liver injury: a descriptive study using the French pharmacovigilance database. Clin Res Hepatol Gastroenterol 44:662\u2013673. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"9806_CR129","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/s41572-019-0105-0","volume":"7","author":"ME Zoubek","year":"2019","unstructured":"Zoubek ME, Pinazo-Bandera J, Ortega-Alonso A, Hern\u00e1ndez N, Crespo J, Contreras F, Medina-C\u00e1liz I, Sanabria-Cabrera J, Sanjuan-Jim\u00e9nez R, Gonz\u00e1lez-Jim\u00e9nez A et al (2019) Liver injury after methylprednisolone pulses: a disputable cause of hepatotoxicity. A case series and literature review. United Eur Gastroenterol J 7:825\u2013837. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"United Eur Gastroenterol J"},{"key":"9806_CR130","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41572-019-0105-0","volume":"53","author":"M Ueno","year":"2023","unstructured":"Ueno M, Takabatake H, Kayahara T, Morimoto Y, Notohara K, Mizuno M (2023) Long-term outcomes of drug\u2010induced autoimmune\u2010like hepatitis after pulse steroid therapy. Hepatol Res 53:1073\u20131083. https:\/\/doi.org\/10.1038\/s41572-019-0105-0","journal-title":"Hepatol Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09806-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09806-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09806-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T23:00:47Z","timestamp":1738710047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09806-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9806"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09806-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"879"}}